Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Alltracel Pharmaceuticals Plc announces Nanopeutics Agreement

Abstract:
Alltracel's Nanopeutics subsidiary signs new Professional Wound Care technology development agreement with ConvaTec

Alltracel Pharmaceuticals Plc announces Nanopeutics Agreement

DUBLIN, Ireland | Posted on November 11th, 2007

Alltracel Pharmaceuticals Plc., ("Alltracel" or "the Company"), (AIM:AP.L), the
healthcare innovation group focused on oral care, wound care, cardiovascular
health and dermal health markets, today announces that its Nanopeutics
subsidiary has signed a collaborative technology development agreement with
ConvaTec, a world-leading manufacturer of ostomy and wound care products with a
25-year heritage of caring for patients.


ConvaTec has been working with Alltracel since November 2006, when the initial
primary concept development agreement was announced with a professional wound
care partner. As per the original agreement, today's new technology agreement
will be funded by ConvaTec and its successful conclusion may lead to an
exclusive royalty bearing license and supply agreement between both companies.


As part of the development work under the previous agreement, Alltracel's
healthcare services division (Alltracel Healthcare Services) was also contracted
by ConvaTec to perform laboratory testing and analysis work. The extension of
the collaboration between Alltracel and ConvaTec will also include similar
laboratory testing and analysis work by Alltracel Healthcare Services.


Alltracel's Chief Executive Officer, Tony Richardson commented:


"We are very pleased to announce our continuing collaboration with ConvaTec. Our
new agreement in the area of professional wound care product development further
supports the strength of Alltracel's development work carried out to date for
ConvaTec and we look forward to progressing the commercialisation of our
professional wound care products in 2008 and beyond. The professional wound
care area is an important market for us and we are happy to be collaborating
with a partner of ConvaTec's caliber and heritage. Alltracel's Nanospider(TM)
technology affords many possibilities in this sector and seeks to improve
product performance and assist in the treatment of many patients."


Michael J Lydon PhD, Vice President Global R&D in ConvaTec commented:


"ConvaTec acknowledges the significant commercial opportunities that
nanotechnology presents in the field of professional wound care. This agreement
recognizes our continuing commitment to develop this technology to enhance
products and offer improved wound care solutions for our patients."

####

About Alltracel
Alltracel, (AIM: AP.L) (www.alltracel.com) the Healthcare Innovation Group is
focused on taking proprietary technology from research right through to
commercialisation in the global healthcare market.

Alltracel Pharmaceuticals Plc., ("Alltracel") was founded in 1996 and is a
public company which listed on London's Alternative Investment Market in July
2001.

With corporate headquarters in Dublin, Ireland; Alltracel has a commercial
office in London, England; R&D subsidiary in the Czech Republic and
manufacturing facilities in Shenzhen, China. Alltracel also has a wide network
of research, development and manufacturing partners in Europe, Asia and North
America.

Alltracel operates via two main divisions Alltracel Healthcare Group and
Alltracel Healthcare Technologies:

Alltracel Healthcare Group is focused on the commercialisation effort behind
proven innovative technologies and services for the global healthcare market.
Alltracel Healthcare Group has a range of stake holdings, joint ventures and
wholly owned business units operating in a variety of healthcare categories
including Wound Care, Oral Care, Dermal Health and Cardiovascular Health.

- Alltracel's specialist Oral Care subsidiary Synpart Limited
(www.synpartlimited.com) with offices in the UK and Germany is the leading
contract supply and manufacturing partner for the European private label
inter-dental market and also partners with a number of leading oral care brands
internationally.

- Alltracel's specialist Nanotechnology subsidiary Nanopeutics s.r.o.
(www.nanopeutics.net) is headquartered in Liberec in the Czech Republic and is
dedicated to the commercialisation of Nanospider(TM)technology for the global
healthcare market.

- Alltracel Healthcare Services provides Scientific Research, Clinical
Trial & Development Services for Healthcare companies seeking a step up in speed
of Healthcare Innovation.

Alltracel Healthcare Technologies specialises in innovation, research,
development and the deployment of proprietary technology in the global
healthcare market. Alltracel Healthcare Technologies has established a
substantial intellectual property portfolio with patents in a number of
healthcare applications areas such as Wound Care, Oral Care, Cardiovascular
Health and Dermal Health.

ConvaTec Information

ConvaTec, a world-leading manufacturer of ostomy and wound care products with a
heritage of caring about patients, is a Bristol-Myers Squibb Company (NYSE: BMY).
Bristol-Myers Squibb is a global pharmaceutical and related health care
products company.

ConvaTec's Wound Therapeutics(TM)franchise pursues a comprehensive approach that
grounds our advanced science in the everyday realities of wound and skin care.
The company's Chronic Care franchise develops innovative products and
product-related services to help people with an ostomy get back to their
everyday activities and live their lives to the fullest. For more information
please visit www.convatec.com.

Wound Therapeutics(TM)is a trademark of ConvaTec, a Division of E.R. Squibb &
Sons, LLC

m-doc(TM)& Phytopeutics(TM)are trademarks of Alltracel Pharmaceuticals plc.

Nanospider(TM)and Nanopeutics(TM)are trademarks controlled by Nanopeutics s.r.o.

For more information, please click here

Contacts:
Dublin: Karen Muldowney
Alltracel: +353 1 235 2162


London: Deborah Scott
Financial Dynamics: +44 207 831 3113

Copyright © Market Wire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Arrowhead Presents ARC-520 and ARC-521 Clinical Data at The International Liver Congress(TM) April 20th, 2017

Nano-SPEARs gently measure electrical signals in small animals: Rice University's tiny needles simplify data gathering to probe diseases, test drugs April 17th, 2017

Nanotubes that build themselves April 14th, 2017

Emergency Use Authorization for Gene-RADAR® Zika Virus Test: FDA Authorization for the Gene-RADAR® Zika Virus Test on the XPRIZE-Winning Gene-RADAR® Platform April 14th, 2017

Announcements

Two-dimensional melting of hard spheres experimentally unravelled after 60 years: First definitive experimental evidence of two-dimensional melting of hard spheres April 21st, 2017

National Conference on Nanomaterials, (NCN-2017) April 21st, 2017

NanoMONITOR shares its latest developments concerning the NanoMONITOR Software and the Monitoring stations April 21st, 2017

Nanomechanics, Inc. Unveils New Product at ICMCTF Show April 25th: Nanoindentation experts will launch the new Gemini that measures the interaction of two objects that are sliding across each other – not merely making contact April 21st, 2017

Patents/IP/Tech Transfer/Licensing

Forge Nano 2017: 1st Quarter Media Update April 20th, 2017

Making Batteries From Waste Glass Bottles: UCR researchers are turning glass bottles into high performance lithium-ion batteries for electric vehicles and personal electronics April 19th, 2017

'Neuron-reading' nanowires could accelerate development of drugs for neurological diseases April 12th, 2017

Laser activated gold pyramids could deliver drugs, DNA into cells without harm: Microstructures create temporary pores in cells March 27th, 2017

Alliances/Trade associations/Partnerships/Distributorships

BASF and Landa partner to create revolutionary pigments for automotive coatings: The alliance combines BASF innovations with Landa nano-pigment technology April 5th, 2017

Leti Announces EU/South Korean Project for World’s First 5G-system Prototype: Coinciding with the 2018 Winter Games in PyeongChang, Korea, Prototype Will Be First Time State-of-the-art Terrestrial Wireless Communication Is Seamlessly Combined with Disruptive Satellite Communicati April 4th, 2017

ATTOPSEMI Technology Joins FDXcelerator Program to Deliver Advanced Non-Volatile Memory IP to GLOBALFOUNDRIES 22 FDX® Technology Platform: Leading-edge I-fuse™ brings higher reliability, smaller cell size and ease of programmability for consumer, automotive, and IoT applications March 27th, 2017

Leti and HORIBA Scientific to Host Webinar on Ultrafast Characterization Tool: Plasma Profiling Time-of-Flight Mass Spectrometer Tool Cuts Optimization Time In Layer Deposition and Fabrication of Wide Range of Applications March 27th, 2017

Research partnerships

Better living through pressure: Functional nanomaterials made easy April 19th, 2017

Shedding light on the absorption of light by titanium dioxide April 14th, 2017

AIM Photonics Presents Cutting-Edge Integrated Photonics Technology Developments to Packed House at OFC 2017, the Optical Networking and Communication Conference & Exhibition April 11th, 2017

Nanoparticles open new window for biological imaging: “Quantum dots” that emit infrared light enable highly detailed images of internal body structures April 10th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project